These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 20435193

  • 1. Prognostic impact of baseline and serial changes in electrocardiographic left ventricular hypertrophy in resistant hypertension.
    Salles GF, Cardoso CR, Fiszman R, Muxfeldt ES.
    Am Heart J; 2010 May; 159(5):833-40. PubMed ID: 20435193
    [Abstract] [Full Text] [Related]

  • 2. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
    Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B, LIFE Study Investigators.
    JAMA; 2004 Nov 17; 292(19):2343-9. PubMed ID: 15547161
    [Abstract] [Full Text] [Related]

  • 3. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
    Okin PM.
    J Electrocardiol; 2009 Nov 17; 42(6):584-8. PubMed ID: 19631946
    [Abstract] [Full Text] [Related]

  • 4. Regression of electrocardiographic left ventricular hypertrophy or strain is associated with lower incidence of cardiovascular morbidity and mortality in hypertensive patients independent of blood pressure reduction - A LIFE review.
    Bang CN, Devereux RB, Okin PM.
    J Electrocardiol; 2014 Nov 17; 47(5):630-5. PubMed ID: 25052475
    [Abstract] [Full Text] [Related]

  • 5. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
    Larstorp AC, Okin PM, Devereux RB, Olsen MH, Ibsen H, Dahlöf B, Kjeldsen SE, Wachtell K.
    J Hum Hypertens; 2011 Mar 17; 25(3):178-85. PubMed ID: 20505749
    [Abstract] [Full Text] [Related]

  • 6. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
    Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlof B, Losartan Intervention for Endpoint reduction in hypertension Study Investigations.
    Circulation; 2003 Aug 12; 108(6):684-90. PubMed ID: 12885747
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
    Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, Edelman JM, Dahlöf B, Devereux RB, LIFE Study Investigators.
    Circulation; 2009 Apr 14; 119(14):1883-91. PubMed ID: 19332468
    [Abstract] [Full Text] [Related]

  • 8. Obesity and ECG left ventricular hypertrophy.
    Muiesan ML, Salvetti M, Di Castelnuovo A, Paini A, Assanelli D, Costanzo S, Badilini F, Vaglio M, Donati MB, Agabiti Rosei E, de Gaetano G, Iacoviello L, Moli-sani Study Investigators.
    J Hypertens; 2017 Jan 14; 35(1):162-169. PubMed ID: 27662187
    [Abstract] [Full Text] [Related]

  • 9. Detection of left ventricular hypertrophy by different electrocardiographic criteria in clinical practice. Findings from the Sara study.
    Calderón A, Barrios V, Escobar C, Ferrer E, Barrios S, González-Pedel V, Montoro P, Navarro-Cid J.
    Clin Exp Hypertens; 2010 May 14; 32(3):145-53. PubMed ID: 20504121
    [Abstract] [Full Text] [Related]

  • 10. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators.
    Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Dahlöf B.
    Hypertension; 2000 Nov 14; 36(5):766-73. PubMed ID: 11082141
    [Abstract] [Full Text] [Related]

  • 11. Combining ECG Criteria for Left Ventricular Hypertrophy Improves Risk Prediction in Patients With Hypertension.
    Okin PM, Hille DA, Kjeldsen SE, Devereux RB.
    J Am Heart Assoc; 2017 Nov 18; 6(11):. PubMed ID: 29151037
    [Abstract] [Full Text] [Related]

  • 12. Gender differences in regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy.
    Okin PM, Gerdts E, Kjeldsen SE, Julius S, Edelman JM, Dahlöf B, Devereux RB, Losartan Intervention for Endpoint Reduction in Hypertension Study Investigators.
    Hypertension; 2008 Jul 18; 52(1):100-6. PubMed ID: 18504323
    [Abstract] [Full Text] [Related]

  • 13. Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study.
    Okin PM, Jern S, Devereux RB, Kjeldsen SE, Dahlöf B, LIFE Study Group.
    Hypertension; 2000 Jan 18; 35(1 Pt 1):13-8. PubMed ID: 10642268
    [Abstract] [Full Text] [Related]

  • 14. Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE Study.
    Okin PM, Devereux RB, Jern S, Julius S, Kjeldsen SE, Dahlöf B.
    Am J Hypertens; 2001 Aug 18; 14(8 Pt 1):775-82. PubMed ID: 11497193
    [Abstract] [Full Text] [Related]

  • 15. Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
    Okin PM, Devereux RB, Nieminen MS, Jern S, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Dahlöf B, LIFE Study Investigators.
    Circulation; 2006 Jan 03; 113(1):67-73. PubMed ID: 16365195
    [Abstract] [Full Text] [Related]

  • 16. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM, Devereux RB, Gerdts E, Snapinn SM, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Lindholm LH, Dahlöf B, LIFE Study Investigators.
    Circulation; 2006 Mar 28; 113(12):1588-96. PubMed ID: 16534012
    [Abstract] [Full Text] [Related]

  • 17. Four ECG left ventricular hypertrophy criteria and the risk of cardiovascular events and mortality in patients with vascular disease.
    van Kleef MEAM, Visseren FLJ, Vernooij JWP, Nathoe HM, Cramer MM, Bemelmans RHH, van der Graaf Y, Spiering W, SMART-study group.
    J Hypertens; 2018 Sep 28; 36(9):1865-1873. PubMed ID: 29878973
    [Abstract] [Full Text] [Related]

  • 18. Clinical implications of electrocardiographic left ventricular strain and hypertrophy in asymptomatic patients with aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study.
    Greve AM, Boman K, Gohlke-Baerwolf C, Kesäniemi YA, Nienaber C, Ray S, Egstrup K, Rossebø AB, Devereux RB, Køber L, Willenheimer R, Wachtell K.
    Circulation; 2012 Jan 17; 125(2):346-53. PubMed ID: 22147903
    [Abstract] [Full Text] [Related]

  • 19. Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension.
    Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Porcellati C.
    J Am Coll Cardiol; 1998 Feb 17; 31(2):383-90. PubMed ID: 9462583
    [Abstract] [Full Text] [Related]

  • 20. Prognostic value of left ventricular hypertrophy in hypertensive patients: A meta-analysis of electrocardiographic studies.
    Zhang H, Hu L, Wei X.
    J Clin Hypertens (Greenwich); 2020 Feb 17; 22(2):254-260. PubMed ID: 31955500
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.